Overview
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents. Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys.
Background
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents. Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class. It is marketed under the brand name Barhemsys.
Indication
Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not received prophylaxis. Oral amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, characterized by positive symptoms with delusions, hallucinations, thought disorders, hostility and suspicious behavior; or primarily negative symptoms (deficit syndrome) with blunted affect, emotional and social withdrawal. Amisulpride also controls secondary negative symptoms in productive conditions as well as affective disorders such as depressive mood or retardation.
Associated Conditions
- Acute Schizophrenia
- Chronic Schizophrenia
- Negative Symptoms
- Post Operative Nausea and Vomiting (PONV)
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2020/09/01 | Early Phase 1 | UNKNOWN | |||
2020/06/24 | Phase 4 | UNKNOWN | |||
2020/04/10 | Not Applicable | Recruiting | |||
2019/10/16 | Early Phase 1 | Completed | |||
2019/03/05 | Not Applicable | Completed | |||
2019/01/14 | Phase 4 | UNKNOWN | |||
2018/08/31 | Phase 4 | Completed | |||
2018/07/11 | Phase 1 | Completed | |||
2016/01/05 | Phase 3 | Completed | |||
2015/09/23 | Not Applicable | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Amisulpride Tablets | 国药准字H20223053 | 化学药品 | 片剂 | 1/30/2022 | |
Amisulpride Tablets | 国药准字H20233774 | 化学药品 | 片剂 | 6/21/2023 | |
Amisulpride Tablets | 国药准字H20223052 | 化学药品 | 片剂 | 1/30/2022 | |
Amisulpride Tablets | 国药准字H20233830 | 化学药品 | 片剂 | 6/30/2023 | |
Amisulpride Tablets | 国药准字H20203565 | 化学药品 | 片剂 | 11/10/2020 | |
Amisulpride Tablets | 国药准字H20203734 | 化学药品 | 片剂 | 12/29/2020 | |
Amisulpride Tablets | 国药准字H20113231 | 化学药品 | 片剂 | 4/24/2020 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
AMISULPRIDE-WGR 400 mg tablet blister pack | 178897 | Medicine | A | 11/3/2011 | |
AMISULPRIDE SCP amisulpride 200 mg uncoated tablet blister pack | 234699 | Medicine | A | 1/29/2016 | |
APO-Amisulpride 100 mg tablet blister pack | 178904 | Medicine | A | 11/3/2011 | |
APO-Amisulpride 50 mg tablet blister pack | 178900 | Medicine | A | 11/3/2011 | |
AMISULPRIDE SANDOZ PHARMA amisulpride 200 mg uncoated tablet blister pack | 234704 | Medicine | A | 1/29/2016 | |
AMISULPRIDE SANDOZ PHARMA amisulpride 100 mg uncoated tablet blister pack | 234708 | Medicine | A | 1/29/2016 | |
AMISULPRIDE-WGR 200 mg tablet blister pack | 178905 | Medicine | A | 11/3/2011 | |
SULPRIX amisulpride 200 mg tablets blister pack | 156048 | Medicine | A | 11/26/2009 | |
SULPRIX amisulpride 50 mg tablets blister pack | 156047 | Medicine | A | 11/26/2009 | |
SOLIAN amisulpride 100mg/mL oral solution bottle | 94484 | Medicine | A | 2/12/2004 |